Are US payers getting to grips with cost-effectiveness analysis?

Are US payers getting to grips with cost-effectiveness analysis?

Download report

Start a conversation

An Xcenda consultant will contact you directly to discuss your needs.

Xcenda Insights

Rainbow-Abstract

Insight

Essential guide to cell and gene therapy (CGT) commercialization

AmerisourceBergen
April 2024

ThinkLive-web-hero-background-1200x800

Insight

Pharma in the field: Barrett's story

Xcenda
February 2024

Vials

Insight

Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond

AmerisourceBergen
January 2024